Penalty Amount
$400,000,000
Attorney General Tong led a coalition of 43 states and territories in announcing a $400 million settlement in principle with Sandoz Inc. to resolve allegations that the generic drug manufacturer engaged in conspiracies to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade. Sandoz will pay approximately $469 million total and implement internal reforms to ensure fair competition and compliance with antitrust laws.
Sandoz Inc. will pay $400 million (with total payments of approximately $469 million) and implement internal reforms and injunctive terms to ensure fair competition and compliance with antitrust laws.
In-house legal teams should review vendor and customer agreements for any clauses that could facilitate anti-competitive behavior, such as pricing coordination, market allocation, or information sharing with competitors. They should also ensure that contracts include robust antitrust compliance provisions and that employees are trained on avoiding improper communications with competitors. Additionally, review any agreements with trade associations or industry groups to ensure they do not inadvertently lead to collusion.
Entity
Sandoz Inc.
Industry
Healthcare"Sandoz Inc."
"$400 million settlement in principle"
"conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade"
"compliance with antitrust laws"
$400.0M
Attorney General Jennifer Davenport joined a coalition of 43 states and territories in announcing a $400 million settlement in principle with Sandoz Inc. to resolve allegations of widespread price-fixing and anticompetitive conduct in the generic drug market. Sandoz will pay approximately $469 million total including prior settlements, and has agreed to internal reforms to ensure fair competition.
$400.0M
Minnesota Attorney General Keith Ellison joined a coalition of 43 states and territories in announcing a $400 million settlement in principle with Sandoz Inc. to resolve allegations that the generic drug manufacturer engaged in conspiracies to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for numerous generic prescription drugs. Sandoz will pay approximately $469 million total including prior settlements, and has agreed to injunctive terms and internal reforms.
$400.0M
Attorney General Phil Weiser joined a coalition of 43 states and territories announcing a $400 million settlement in principle with Sandoz Inc. to resolve allegations that the generic drug manufacturer engaged in conspiracies to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade. Sandoz will pay approximately $469 million including previous settlements and agreed to meaningful reforms to ensure fair competition and compliance with antitrust laws.
$694.0M
Connecticut Attorney General William Tong joined 40 other state attorneys general in a settlement with Credit Acceptance Corporation (CAC), one of the nation's largest subprime auto lenders, resolving allegations that CAC originated loans it knew or should have known consumers could not afford and encouraged or failed to prevent dealers from 'packing' CAC loans with unwanted Vehicle Service Contract (VSC) and GAP products. The settlement, announced September 17, 2026 and effective November 2, 2026, directs $694 million in cash restitution and debt relief to consumers, plus an additional $15 million to the states, and imposes injunctive lending reforms. Note: this is a consumer-protection/lending enforcement action rather than a data privacy matter; the violation categories are best-fit mappings to the available taxonomy.
Connecticut Attorney General William Tong issued an advisory that newly enacted privacy laws take effect October 1, 2026, including Public Act 26-64 (SB4), which amends the Connecticut Data Privacy Act, and Public Act 26-15 (SB5), which established the Connecticut Artificial Intelligence Responsibility and Transparency Act (CART Act). The new laws regulate surveillance pricing, facial recognition technology, genetic data collected by direct-to-consumer testing companies, a ban on the sale of precise geolocation data, a data broker registry, AI use in employment decisions, and chatbots offered to children. No enforcement action was taken; this is prospective guidance alerting consumers and businesses to new rights and compliance requirements.
$384.2M
Connecticut joined 39 other states and the federal government in a $384 million False Claims Act settlement with Abbott Laboratories over allegations that the company failed to manufacture powder infant formula and nutritional therapy products in compliance with federal and state requirements at its Sturgis, Michigan, and Casa Grande, Arizona facilities. Abbott allegedly manufactured formula in conditions that risked microorganism contamination and failed to disclose contamination test results to the FDA during 2019 and 2022 inspections. The settlement resolves claims that Abbott caused false claims to be submitted to the WIC program and state Medicaid programs between January 1, 2018, and December 31, 2022.